TEG® 6s coagulation testing with a novel heparin neutralization cartridge: Technical validation and determination of normal reference ranges
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae088 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Jan Hartmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Office, Haemonetics Corporation, Boston, MA, US. Hauptthemen laut MEDLINE: Thrombelastography, Heparin, Blood Coagulation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Haemonetics Corporation.
Abstract (Originalsprache)
Objectives
We sought to establish normal reference ranges (NRRs) for a novel TEG 6s cartridge (TEG 6s Citrated: K, KH, RTH, FFH [Global Hemostasis]) (Haemonetics Corporation, Boston, MA, US).
Methods
Healthy volunteers (≥18 years of age) included in this single-arm study provided single samples of whole blood. Primary end points included TEG parameters in the citrated kaolin (CK), CK with heparinase (CKH), RapidTEG with heparinase (CRTH), and functional fibrinogen with heparinase (CFFH) assays.
Results
Evaluable data were contributed by 164 volunteers (48.8% female; 62% White/Caucasian). The following NRRs were established: CK maximum amplitude (MA), 51.0 to 67.6 mm; CKH-MA, 51.8 to 67.9 mm; CRTH-MA, 53.0 to 68.9 mm; CFFH-MA, 15.3 to 34.4 mm; CK reaction time, 5.0 to 9.1 minutes; CKH reaction time, 4.9 to 9.4 minutes; CKH lysis 30 minutes after MA, 0% to 3.2%. Duplicate measurements demonstrated high reproducibility. CFFH-MA correlated with Clauss fibrinogen concentration (Pearson correlation coefficient, 0.74). Laboratory-based studies demonstrated maintenance of the relationship between CFFH-MA and fibrinogen up to 1344 mg/dL (hyperfibrinogenemic samples) and acceptability of heparin neutralization up to concentrations of low molecular weight and unfractionated heparin of 1.3 IU/mL and 5 IU/mL, respectively.
Conclusions
This study established NRRs for the Global Hemostasis cartridge and serves as a proof of concept for the validity of results obtained using this cartridge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Medical Office, Haemonetics Corporation, Boston, MA, US.
- Machaon Diagnostics, Inc, Berkeley, CA, US.
- Cardiovascular Research Institute, Loyola University Chicago, Maywood, IL, US.
- ClinStatDevice, Lexington, MA, US.
- Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, CA, US.
- Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, US.
ORCID-Profile: Jan Hartmann
Förderung
- Haemonetics Corporation
Zitieren
APA
Hartmann, J., Dias, J., Shilo, A., Bynagari, Y., Garrett, B., Jeske, W., Manukyan, Z., Mkhitaryan, K., Adelmann, D., Subramaniam, K., & Sakai, T. (2025). TEG® 6s coagulation testing with a novel heparin neutralization cartridge: Technical validation and determination of normal reference ranges. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae088
Vancouver
Hartmann J, Dias J, Shilo A, Bynagari Y, Garrett B, Jeske W, et al. TEG® 6s coagulation testing with a novel heparin neutralization cartridge: Technical validation and determination of normal reference ranges. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae088
BibTeX
@article{Hartmann2025,
author = {Hartmann, Jan and Dias, Joao and Shilo, Alexandra and Bynagari, Yamini and Garrett, Brandon and Jeske, Walter and Manukyan, Zorayr and Mkhitaryan, Karen and Adelmann, Dieter and Subramaniam, Kathirvel and Sakai, Tetsuro},
title = {TEG® 6s coagulation testing with a novel heparin neutralization cartridge: Technical validation and determination of normal reference ranges},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae088}
}
EUVIMED